Treatment Information

Back

Breast Cancer treatment details. Hormone.

Rigshospitalet, Copenhagen, Denmark.

Survival: monthsCountry:Denmark
Toxiciy Grade:City/State/Province:Copenhagen
Treatments:HormoneHospital:Rigshospitalet
Drugs:Journal:Link
Date:Jun 2003

Description:

Patients: This Phase III study involved 916 advanced breast cancer patients (postmenopausal) with hormone-receptor positive or unknown tumors. Patients were divided into two groups: Group 1 had 458 patients, and Group 2 had 458 patients.

Treatment: Patients in group 1 were administered letrozole (femara, an aromatase inhibitor that prevents estrogen biosynthesis).

Toxicity: Toxicities associated with the treatment for patients in group 1 (“irrespective of relationship” to the treatment) included: bone fractures of any cause (5.3%), bone pain, hot flushes, back pain, dyspnea, nausea, arthralgia, cough, fatigue, and constipation.

Results: Median overall survival for patients in group 1 was 34 months.

Support: The study was supported by Novartis Pharma and the many of the study’s authors held shares in the company and/or acted as consultants for the company and/or did contract work for the company and/or served as an officer or Board member of the company and/or received more than $2,000 a year from the company. In addition, three of the authors are employees of Novartis Pharma. Novartis manufactures femara.




Back